441 related articles for article (PubMed ID: 15653658)
1. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
3. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
Bodei L; Cremonesi M; Ferrari M; Pacifici M; Grana CM; Bartolomei M; Baio SM; Sansovini M; Paganelli G
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1847-56. PubMed ID: 18427807
[TBL] [Abstract][Full Text] [Related]
5. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
7. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
8.
Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
[TBL] [Abstract][Full Text] [Related]
9. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Van Binnebeek S; Baete K; Vanbilloen B; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Haustermans K; Van Cutsem E; Verbruggen A; Bogaerts K; Verslype C; Deroose CM
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1141-57. PubMed ID: 24668274
[TBL] [Abstract][Full Text] [Related]
10. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
11. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
12. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
[TBL] [Abstract][Full Text] [Related]
13. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
Paganelli G; Bodei L; Handkiewicz Junak D; Rocca P; Papi S; Lopera Sierra M; Gatti M; Chinol M; Bartolomei M; Fiorenza M; Grana C
Biopolymers; 2002; 66(6):393-8. PubMed ID: 12658726
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
[TBL] [Abstract][Full Text] [Related]
15. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
16. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
17. [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
Stahl A; Schachoff S; Beer A; Winter A; Wester HJ; Scheidhauer K; Schwaiger M; Wolf I
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1328-36. PubMed ID: 16645839
[TBL] [Abstract][Full Text] [Related]
18. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
19. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
